Inhibition of vascular calcification by inositol phosphates derivatized with ethylene glycol oligomers.

6-Phytase / metabolism Adenine / adverse effects Animals Cells, Cultured Drug Evaluation, Preclinical / methods Dynamic Light Scattering Ethylene Glycol / chemistry Humans Injections, Subcutaneous Inositol Phosphates / chemistry Male Muscle, Smooth, Vascular / cytology Rats, Sprague-Dawley Uremia / drug therapy Vascular Calcification / chemically induced X-Ray Diffraction

Journal

Nature communications

ISSN: 2041-1723

Titre abrégé: Nat Commun

Pays: England

ID NLM: 101528555

Informations de publication

Date de publication:
05 02 2020

Historique:

received: 12 04 2019

accepted: 18 12 2019

entrez: 7 2 2020

pubmed: 7 2 2020

medline: 13 5 2020

Statut: epublish

Résumé

Myo-inositol hexakisphosphate (IP6) is a natural product known to inhibit vascular calcification (VC), but with limited potency and low plasma exposure following bolus administration. Here we report the design of a series of inositol phosphate analogs as crystallization inhibitors, among which 4,6-di-O-(methoxy-diethyleneglycol)-myo-inositol-1,2,3,5-tetrakis(phosphate), (OEG

Identifiants

DOI: 10.1038/s41467-019-14091-4 PMID: 32024848 PMC: PMC7002685

pubmed: 32024848

doi: 10.1038/s41467-019-14091-4

pii: 10.1038/s41467-019-14091-4

pmc: PMC7002685

doi:

Substances chimiques

Inositol Phosphates 0

6-Phytase EC 3.1.3.26

Ethylene Glycol FC72KVT52F

Adenine JAC85A2161

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

721

Subventions

Organisme : British Heart Foundation

ID : RG/16/10/32375

Pays : United Kingdom

Références

Demer, L. L. & Tintut, Y. Vascular calcification: pathobiology of a multifaceted disease. Circulation 104, 1881–1883 (2001).

pubmed: 11602487 doi: 10.1161/circ.104.16.1881 pmcid: 11602487

Towler, D. A. Vascular calcification: a perspective on an imminent disease epidemic. IBMS BoneKEy 5, 41–58 (2008).

doi: 10.1138/20080298

Shanahan, C. M. Inflammation ushers in calcification: a cycle of damage and protection? Circulation 116, 2782–2785 (2007).

pubmed: 18071088 doi: 10.1161/CIRCULATIONAHA.107.749655 pmcid: 18071088

Guérin, A. P., London, G. M., Marchais, S. J. & Metivier, F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol. Dial. Transplant. 15, 1014–1021 (2000).

pubmed: 10862640 doi: 10.1093/ndt/15.7.1014 pmcid: 10862640

Sangiorgi, G. et al. Arterial calcification and not lumen stenosis is highly correlated with atherosclerotic plaque burden in humans: a histologic study of 723 coronary artery segments using nondecalcifying methodology. J. Am. Coll. Cardiol. 31, 126–133 (1998).

pubmed: 9426030 doi: 10.1016/S0735-1097(97)00443-9 pmcid: 9426030

Pohle, K. et al. Progression of aortic valve calcification. Circulation 104, 1927–1932 (2001).

pubmed: 11602496 doi: 10.1161/hc4101.097527 pmcid: 11602496

Maher, E. R., Young, G., Smyth-Walsh, B., Pugh, S. & Curtis, J. R. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 330, 875–877 (1987).

doi: 10.1016/S0140-6736(87)91370-5

Rogers, M. A. & Aikawa, E. Cardiovascular calcification: artificial intelligence and big data accelerate mechanistic discovery. Nat. Rev. Cardiol. 16, 261–274 (2018).

Mizobuchi, M., Towler, D. & Slatopolsky, E. Vascular calcification: the killer of patients with chronic kidney disease. J. Am. Soc. Nephrol. 20, 1453–1464 (2009).

pubmed: 19478096 doi: 10.1681/ASN.2008070692 pmcid: 19478096

Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E. & Hsu, C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 351, 1296–1305 (2004).

pubmed: 15385656 doi: 10.1056/NEJMoa041031

Vanholder, R. et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol. Dial. Transplant. 20, 1048–1056 (2005).

pubmed: 15814534 doi: 10.1093/ndt/gfh813

Nitschke, Y. et al. Generalized arterial calcification of infancy and pseudoxanthoma elasticum can be caused by mutations in either ENPP1 or ABCC6. Am. J. Hum. Genet. 90, 25–39 (2012).

pubmed: 22209248 pmcid: 3257960 doi: 10.1016/j.ajhg.2011.11.020

Bartstra, J. W., De Jong, P. A. & Spiering, W. Accelerated peripheral vascular aging in pseudoxanthoma elasticum—proof of concept for arterial calcification—induced cardiovascular disease. Aging 11, 1062–1064 (2019).

pubmed: 30745467 pmcid: 6382434 doi: 10.18632/aging.101821

Jahnen-Dechent, W. et al. Cloning and targeted deletion of the mouse fetuin gene. J. Biol. Chem. 272, 31496–31503 (1997).

pubmed: 9395485 doi: 10.1074/jbc.272.50.31496

Luo, G. et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386, 78–81 (1997).

pubmed: 9052783 doi: 10.1038/386078a0

Fleisch, H. & Bisaz, S. Mechanism of calcification: inhibitory role of pyrophosphate. Nature 195, 911 (1962).

pubmed: 13893487 doi: 10.1038/195911a0

Schantl, A. E., Ivarsson, M. E. & Leroux, J.-C. Investigational pharmacological treatments for vascular calcification. Adv. Ther. 2, 1–16 (2018).

Tonelli, M., Pannu, N. & Manns, B. Oral phosphate binders in patients with kidney failure. N. Engl. J. Med. 362, 1312–1324 (2010).

pubmed: 20375408 doi: 10.1056/NEJMra0912522

Heiss, A. et al. Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles. J. Biol. Chem. 283, 14815–14825 (2008).

pubmed: 18364352 doi: 10.1074/jbc.M709938200

Wald, J. et al. Formation and stability kinetics of calcium phosphate–fetuin-A colloidal particles probed by time-resolved dynamic light scattering. Soft Matter 7, 2869–2874 (2011).

doi: 10.1039/c0sm01191f

Herrmann, M. et al. Clearance of fetuin-A-containing calciprotein particles is mediated by scavenger receptor-A. Circ. Res. 111, 575–584 (2012).

pubmed: 22753077 doi: 10.1161/CIRCRESAHA.111.261479

Pasch, A. et al. Nanoparticle-based test measures overall propensity for calcification in serum. J. Am. Soc. Nephrol. 23, 1744–1752 (2012).

pubmed: 22956818 pmcid: 3458464 doi: 10.1681/ASN.2012030240

Kuro-o, M. Klotho, phosphate and FGF-23 in ageing and disturbed mineral metabolism. Nat. Rev. Nephrol. 9, 650–660 (2013).

pubmed: 23774819 doi: 10.1038/nrneph.2013.111

Köppert, S. et al. Cellular clearance and biological activity of calciprotein particles depend on their maturation state and crystallinity. Front. Immunol. 9, 1–17 (2018).

doi: 10.3389/fimmu.2018.01991

Kuro-o, M. Calciprotein particle (CPP): a true culprit of phosphorus woes? Nefrologia 34, 1–4 (2014).

pubmed: 24336683

Miura, Y. et al. Identification and quantification of plasma calciprotein particles with distinct physical properties in patients with chronic kidney disease. Sci. Rep. 8, 1256 (2018).

pubmed: 29352150 pmcid: 5775250 doi: 10.1038/s41598-018-19677-4

Smith, E. R. et al. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol. Dial. Transplant. 27, 1957–1966 (2012).

pubmed: 22105144 doi: 10.1093/ndt/gfr609

Hamano, T. et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J. Am. Soc. Nephrol. 21, 1998–2007 (2010).

pubmed: 20947626 pmcid: 3014014 doi: 10.1681/ASN.2009090944

Chen, W. et al. Patients with advanced chronic kidney disease and vascular calcification have a large hydrodynamic radius of secondary calciprotein particles. Nephrol. Dial. Transplant. 34, 992–1000 (2019).

pubmed: 29788425 doi: 10.1093/ndt/gfy117

Aghagolzadeh, P. et al. Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-α. Atherosclerosis 251, 404–414 (2016).

pubmed: 27289275 doi: 10.1016/j.atherosclerosis.2016.05.044 pmcid: 27289275

Bertazzo, S. et al. Nano-analytical electron microscopy reveals fundamental insights into human cardiovascular tissue calcification. Nat. Mater. 12, 576–583 (2013).

pubmed: 23603848 pmcid: 5833942 doi: 10.1038/nmat3627

Reznikov, N., Steele, J. A. M., Fratzl, P. & Stevens, M. M. A materials science vision of extracellular matrix mineralization. Nat. Rev. Mater. 1, 16041 (2016).

doi: 10.1038/natrevmats.2016.41

Joshi, N. V. et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: a prospective clinical trial. Lancet 383, 705–713 (2014).

pubmed: 24224999 doi: 10.1016/S0140-6736(13)61754-7 pmcid: 24224999

Irkle, A. et al. Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography. Nat. Commun. 6, 7495 (2015).

pubmed: 26151378 pmcid: 4506997 doi: 10.1038/ncomms8495

Nakahara, T. et al. Coronary artery calcification: from mechanism to molecular imaging. JACC Cardiovasc. Imaging 10, 582–593 (2017).

pubmed: 28473100 doi: 10.1016/j.jcmg.2017.03.005 pmcid: 28473100

Chen, J. et al. Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease. JAMA Cardiol. 2, 635–643 (2017).

pubmed: 28329057 pmcid: 5798875 doi: 10.1001/jamacardio.2017.0363

London, G. M. et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 18, 1731–1740 (2003).

pubmed: 12937218 doi: 10.1093/ndt/gfg414 pmcid: 12937218

Shantouf, R. S. et al. Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. Am. J. Nephrol. 31, 419–425 (2010).

pubmed: 20389057 pmcid: 2883846 doi: 10.1159/000294405

Irvine, R. F. & Schell, M. J. Back in the water: the return of the inositol phosphates. Nat. Rev. Mol. Cell Biol. 2, 327–338 (2001).

pubmed: 11331907 doi: 10.1038/35073015 pmcid: 11331907

Grases, F. et al. Phytate (myo-inositol hexakisphosphate) inhibits cardiovascular calcifications in rats. Front. Biosci. 11, 136–142 (2006).

pubmed: 16146720 doi: 10.2741/1786 pmcid: 16146720

Van den Berg, C. J., Hill, L. F. & Stanbury, S. W. Inositol phosphates and phytic acid as inhibitors of biological calcification in the rat. Clin. Sci. 43, 377–383 (1972).

pubmed: 5077515 doi: 10.1042/cs0430377 pmcid: 5077515

Brandenburg, V. M. et al. Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis. J. Nephrol. 32, 811–821 (2019).

pubmed: 31401795 doi: 10.1007/s40620-019-00631-0 pmcid: 31401795

Perelló, J. et al. First-time-in-human randomized clinical trial in healthy volunteers and haemodialysis patients with SNF472, a novel inhibitor of vascular calcification. Br. J. Clin. Pharmacol. 84, 2867–2876 (2018).

pubmed: 30280390 pmcid: 6255995 doi: 10.1111/bcp.13752

Raggi, P. et al. Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized, phase 2b study. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.119.044195 (2019).

Ferrer, M. D. et al. Characterization of SNF472 pharmacokinetics and efficacy in uremic and non-uremic rats models of cardiovascular calcification. PLoS ONE 13, 1–19 (2018).

Perelló, J. et al. SNF472, a novel inhibitor of vascular calcification, could be administered during hemodialysis to attain potentially therapeutic phytate levels. J. Nephrol. 31, 287–296 (2018).

pubmed: 29350348 pmcid: 5829128 doi: 10.1007/s40620-018-0471-9

Huang, X. et al. Characterization of calcium phosphate nanoparticles based on a PEGylated chelator for gene delivery. ACS Appl. Mater. Interfaces 9, 10435–10445 (2017).

pubmed: 28266206 doi: 10.1021/acsami.6b15925 pmcid: 28266206

Giger, E. V., Castagner, B., Räikkönen, J., Mönkkönen, J. & Leroux, J. C. siRNA transfection with calcium phosphate nanoparticles stabilized with PEGylated chelators. Adv. Healthc. Mater. 2, 134–144 (2013).

pubmed: 23184402 doi: 10.1002/adhm.201200088 pmcid: 23184402

Ekladious, I., Colson, Y. L. & Grinstaff, M. W. Polymer–drug conjugate therapeutics: advances, insights and prospects. Nat. Rev. Drug Discov. 18, 273–294 (2018).

doi: 10.1038/s41573-018-0005-0

Verhulst, A., Neven, E. & D’Haese, P. C. Characterization of an animal model to study risk factors and new therapies for the cardiorenal syndrome, a major health issue in our aging population. Cardiorenal Med. 7, 234–244 (2017).

pubmed: 28736564 pmcid: 5511997 doi: 10.1159/000462984

Ivarsson, M. E. et al. Small-molecule allosteric triggers of clostridium difficile toxin B auto-proteolysis as a therapeutic strategy. Cell Chem. Biol. 26, 17–26 (2019).

pubmed: 30482680 doi: 10.1016/j.chembiol.2018.10.002

Smith, E. R., Hewitson, T. D., Hanssen, E. & Holt, S. G. Biochemical transformation of calciprotein particles in uraemia. Bone 110, 355–367 (2018).

pubmed: 29499417 doi: 10.1016/j.bone.2018.02.023

Suvorova, E. & Buffat, P. Electron diffraction and high resolution transmission electron microscopy in the characterization of calcium phosphate precipitation from aqueous solutions under biomineralization conditions. Eur. Cells Mater. 41, 27–42 (2001).

doi: 10.22203/eCM.v001a04

Forsythe, R. O. et al. 18F-sodium fluoride uptake in abdominal aortic aneurysms: The SoFIA3 Study. J. Am. Coll. Cardiol. 71, 513–523 (2018).

pubmed: 29406857 pmcid: 5800891 doi: 10.1016/j.jacc.2017.11.053

Sharaf El Din, U. A. A., Salem, M. M. & Abdulazim, D. O. Vascular calcification: when should we interfere in chronic kidney disease patients and how? World J. Nephrol. 5, 398–417 (2016).

pubmed: 27648404 pmcid: 5011247 doi: 10.5527/wjn.v5.i5.398

Reynolds, J. L. et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J. Am. Soc. Nephrol. 15, 2857–2867 (2004).

pubmed: 15504939 doi: 10.1097/01.ASN.0000141960.01035.28

Kapustin, A. N. et al. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ. Res. 116, 1312–1323 (2015).

pubmed: 25711438 doi: 10.1161/CIRCRESAHA.116.305012

Iyemere, V. P., Proudfoot, D., Weissberg, P. L. & Shanahan, C. M. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J. Intern. Med. 260, 192–210 (2006).

pubmed: 16918817 doi: 10.1111/j.1365-2796.2006.01692.x

Shanahan, C. M. Mechanisms of vascular calcification in CKD - Evidence for premature ageing? Nat. Rev. Nephrol. 9, 661–670 (2013).

pubmed: 24018414 doi: 10.1038/nrneph.2013.176

Neven, E. G., De Schutter, T. M., De Broe, M. E. & D’Haese, P. C. Cell biological and physicochemical aspects of arterial calcification. Kidney Int. 79, 1166–1177 (2011).

pubmed: 21412217 doi: 10.1038/ki.2011.59

Cai, M. M. X., Smith, E. R., Tan, S. J., Hewitson, T. D. & Holt, S. G. The role of secondary calciprotein particles in the mineralisation paradox of chronic kidney disease. Calcif. Tissue Int. 101, 570–580 (2017).

pubmed: 28861648 doi: 10.1007/s00223-017-0313-0

Aghagolzadeh, P. et al. Hydrogen sulfide attenuates calcification of vascular smooth muscle cells via KEAP1/NRF2/NQO1 activation. Atherosclerosis 265, 78–86 (2017).

pubmed: 28865326 doi: 10.1016/j.atherosclerosis.2017.08.012

Smith, E. R., Hanssen, E., McMahon, L. P. & Holt, S. G. Fetuin-A-containing calciprotein particles reduce mineral stress in the macrophage. PLoS ONE 8, e60904 (2013).

pubmed: 23577176 pmcid: 3620111 doi: 10.1371/journal.pone.0060904

Zavaczki, E. et al. Hydrogen sulfide inhibits the calcification and osteoblastic differentiation of vascular smooth muscle cells. Kidney Int. 80, 731–739 (2011).

pubmed: 21716261 pmcid: 3257044 doi: 10.1038/ki.2011.212

Eiseman, J., Lan, J., Guo, J., Joseph, E. & Vucenik, I. Pharmacokinetics and tissue distribution of inositol hexaphosphate in C.B17 SCID mice bearing human breast cancer xenografts. Metabolism 60, 1465–1474 (2011).

pubmed: 21489580 doi: 10.1016/j.metabol.2011.02.015

De Schutter, T. M. et al. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int. 83, 1109–1117 (2013).

pubmed: 23486515 pmcid: 3674404 doi: 10.1038/ki.2013.34

Hecht, H. S. Coronary artery calcium scanning: past, present, and future. JACC Cardiovasc. Imag. 8, 579–596 (2015).

doi: 10.1016/j.jcmg.2015.02.006

Kramer, H., Toto, R., Peshock, R., Cooper, R. & Victor, R. Association between chronic kidney disease and coronary artery calcification: The Dallas Heart Study. J. Am. Soc. Nephrol. 16, 507–513 (2005).

pubmed: 15601745 doi: 10.1681/ASN.2004070610

Dweck, M. R. et al. 18F-Sodium fluoride uptake is a marker of active calcification and disease progression in patients with aortic stenosis. Circ. Cardiovasc. Imaging 7, 371–378 (2014).

pubmed: 24508669 doi: 10.1161/CIRCIMAGING.113.001508

Chen, Y., Bal, B. S. & Gorski, J. P. Calcium and collagen binding properties of osteopontin, bone sialoprotein, and bone acidic glycoprotein-75 from bone. J. Biol. Chem. 267, 24871–24878 (1992).

pubmed: 1447223 pmcid: 1447223

Heiss, A. et al. Structural basis of calcification inhibition by α2-HS glycoprotein/fetuin-A: formation of colloidal calciprotein particles. J. Biol. Chem. 278, 13333–13341 (2003).

pubmed: 12556469 doi: 10.1074/jbc.M210868200 pmcid: 12556469

Smith, E. R., Hewitson, T. D., Cai, M. M. X. & Aghagolzadeh, P. A novel fluorescent probe-based flow cytometric assay for mineral-containing nanoparticles in serum. Sci. Rep. 7, 5686 (2017).

pubmed: 28720774 pmcid: 5515983 doi: 10.1038/s41598-017-05474-y

Mattheolabakis, G. et al. Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-ibuprofen. J. Pharmacol. Exp. Ther. 351, 61–66 (2014).

pubmed: 25047517 doi: 10.1124/jpet.114.217208 pmcid: 25047517

Neven, E. et al. Disturbances in bone largely predict aortic calcification in an alternative rat model developed to study both aascular and bone pathology in chronic kidney disease. J. Bone Miner. Res. 30, 2313–2324 (2015).

pubmed: 26108730 doi: 10.1002/jbmr.2585 pmcid: 26108730

Evenepoel, P., Behets, G. J., Viaene, L. & D’Haese, P. C. Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. Kidney Int. 91, 469–476 (2017).

pubmed: 27998642 doi: 10.1016/j.kint.2016.10.008 pmcid: 27998642

Ivarsson, M. M., Castagner, B., Leroux, J. J.-C. & Pasch, A. Inositol derivatives for use in pathological crystallization. Int. Pat. Appl. WO 2017/098047 A1 (2019).

Castagner, B., Leroux, J.-C., Ivarsson, M., Schneider, G. & Pratsinis, A. Pharmaceutical compounds for use in the therapy of clostridium difficile infection. US Pat. 9751903 B2 (2017).

Oakley, A. J. The structure of Aspergillus niger phytase PhyA in complex with a phytate mimetic. Biochem. Biophys. Res. Commun. 397, 745–749 (2010).

pubmed: 20541524 doi: 10.1016/j.bbrc.2010.06.024 pmcid: 20541524

Sousa, E. H. S., Garay, P. A., Tinianow, J. N. & Gerber, N. C. Development of a spectrophotometric assay for cyclase activity. Anal. Biochem. 348, 57–63 (2006).

pubmed: 16289346 doi: 10.1016/j.ab.2005.10.008 pmcid: 16289346

Shanahan, C. M. & Proudfoot, D. Human Vascular Smooth Muscle Cell Culture. in Human Cell Culture Protocols (eds Mitry, R. & Hughes R.) Vol. 806, 301–336 (Humana Press, 2012).

Kelynack, K. J. & Holt, S. G. An In Vitro Murine Model of Vascular Smooth Muscle Cell Mineralization. in Kidney Research: Experimental Protocols (eds Hewitson, T. D., Smith, E. R. & Holt, S. G.) Vol. 466, 193–203 (Humana Press, 2016).

Daigneault, M., Preston, J. A., Marriott, H. M., Whyte, M. K. B. & Dockrell, D. H. The identification of markers of macrophage differentiation in PMA-stimulated THP-1 cells and monocyte-derived macrophages. PLoS ONE 5, 1–10 (2010).

doi: 10.1371/journal.pone.0008668

Zhang, Y., Huo, M., Zhou, J. & Xie, S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Prog. Biomed. 99, 306–314 (2010).

doi: 10.1016/j.cmpb.2010.01.007

Phan, O. et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 112, 2875–2882 (2005).

pubmed: 16267260 doi: 10.1161/CIRCULATIONAHA105.541854

Jaffe, M. Ueber den niederschlag, welchen pikrinsäure in normalem harn erzeugt und über eine neue reaction des kreatinins. Z. Physiol. Chem. 10, 391–400 (1886).